News & Blog
News & Blog
Astellas shares that US FDA cleared their IND with Fast Track designation for Phase 1 trial of their investigational gene therapy for the treatment of cardiomyopathy in FA
In a communication to FARA and the FA Community, Astellas shared that the US FDA has cleared their Investigational New Drug with a fast ...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce Collaborative Research Grant Using Novel Gene Editing Technology to Address Root Cause of Friedreich’s Ataxia Disease
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Meet the Community – Gabriel Queiroz Pereira & Fernanda Cenci Queiroz
rideATAXIA Gainesville 2024 Recap
Meet the Community – Joe Tyler
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 2024 – Advocacy Newsletter
